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Abstract
Introduction: Basal-like breast cancers behave more aggressively despite the presence of a dense lymphoid
infiltrate. We hypothesised that immune suppression in this subtype may be due to T regulatory cells (Treg)
recruitment driven by hypoxia-induced up-regulation of CXCR4 in Treg.
Methods: Immunoperoxidase staining for FOXP3 and CXCL12 was performed on tissue microarrays from 491
breast cancers. The hypoxia-associated marker carbonic anhydrase IX (CA9) and double FOXP3/CXCR4 staining
were performed on sections from a subset of these cancers including 10 basal-like and 11 luminal cancers
matched for tumour grade.
Results: High Treg infiltration correlated with tumour CXCL12 positivity (OR 1.89, 95% CI 1.22 to 2.94, P = 0.004)
and basal phenotype (OR 3.14, 95% CI 1.08 to 9.17, P = 0.004) in univariate and multivariate analyses. CXCL12
positivity correlated with improved survival (P = 0.005), whereas high Treg correlated with shorter survival for all
breast cancers (P = 0.001), luminal cancers (P < 0.001) and basal-like cancers (P = 0.040) that were confirmed in a
multivariate analysis (OR 1.61, 95% CI 1.02 to 2.53, P = 0.042). In patients treated with hormone therapy, high Treg
were associated with a shorter survival in a multivariate analysis (OR 1.78, 95% CI 1.01 to 3.15, P = 0.040). There was
a tendency for luminal cancers to show CXCL12 expression (102/138, 74%) compared to basal-like cancers (16/27,
59%), which verged on statistical significance (P = 0.050). Up-regulation of CXCR4 in Treg correlated with the basal-
like phenotype (P = 0.029) and tumour hypoxia, as indicated by CA9 expression (P = 0.049).
Conclusions: Our data show that in the setting of hypoxia and CXCR4 up-regulation in Treg, CXCL12 expression
may have the negative consequence of enhancing Treg recruitment and suppressing the anti-tumour immune
response.
Introduction
Cancer is rarely suppressed by the host immune
response since tumour cells acquire immune tolerance.
The failure of an anti-cancer immune response may be
due to a specific subpopulation of regulatory T cells
(Treg) [1]. Treg down-regulate the activation and expan-
sion of self-reactive lymphocytes [2], and are crucial for
the repression of autoimmune disorders and transplant
rejection [3,4]. Although the role of Treg in cancer has
not been fully elucidated, these cells are likely to be
responsible for maintaining the self-tolerance that may
hinder the generation and activity of anti-tumour reac-
tive T cells [2]. This is supported by observations that
depletion of Treg [1,5,6] and transforming growth b
secreted by Treg [7,8] correlate with an enhanced
immune response to cancer vaccines. Recently we and
others have demonstrated that tumour infiltration by
Treg, independent of other lymphoid populations, is
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cancers [9-13].
Breast cancers are heterogeneous and one recognised
subgroup, basal-like breast cancers, derive their name
from the characteristic expression of basal cytokeratins
(CK) 5, 14 and 17 [14,15]. These tumours account for
up to 15% of all invasive breast cancers [16], and are
frequently observed in patients with BRCA1-related can-
cers [17]. Despite the presence of a dense lymphoid
infiltrate on histology, which is suggestive of an anti-
tumour immune response [17], they are associated with
am o r ea g g r e s s i v ec l i n i c a lcourse characterised by
shorter survival and a higher risk of metastasis [17]. We
hypothesize that this is due, in part, to suppression of
the immune response by Treg.
In non-neoplastic tissues, Treg are recruited by che-
mokines such as CXCL12 secreted by bone marrow,
lymph node and inflammatory cells [18], a mechanism
that is replicated in tumours through chemokine secre-
tion by neoplastic cells [18]. Thus CXCL12, which binds
to its cognate receptor CXCR4 expressed by Treg, has
been implicated in the recruitment of Treg in a number
of tumours including ovarian cancer [19], adenocarci-
noma of the lung [20], malignant mesothelioma [21],
and the myelodysplastic syndromes [22]. CXCR4 expres-
sion is induced under hypoxic stress via activation of
the HIF pathway in a number of cell types including B
lymphocytes [23], tumour associated monocytes and
endothelial cells [24], microglia [25], multipotent stem
cells, stromal cells [26,27], cardiac monocytes and fibro-
blasts [28]. Furthermore, the HIF pathway enhances the
immunosuppressive activity of Treg by promoting the
expression of their lineage transcriptional regulator
FOXP3 [29]. Given the role of hypoxia in T cell activa-
tion [30,31], and also specifically in Treg [29], we
hypothesised that Treg recruitment is dependent on
both CXCL12 production by tumour cells and hypoxia-
induced CXCR4 expression in Treg. We further
hypothesize that since basal-like tumours have an
enhanced hypoxic drive [32] this mechanism may be
prominent in basal-like breast cancer.
We, therefore, investigated CXCR4 expression in Treg,
together with the expression of CA9 and CXCL12 in
basal-like and other subtypes of breast cancers. The sig-
nificance of this project lies in the rational design of
tumour vaccine approaches or blocking antibodies [33].
Therapies targeting Treg are entering clinical trials
[34,35]; therefore, it is important to quantify Treg num-
bers and to assess factors that may affect their recruit-
ment to the tumour microenvironment. Thus, should
findings suggest that hypoxia driven recruitment of Treg
via the CXCL12/CXCR4 axis plays a significant role in
basal-like tumours, therapies targeting CXCL12/CXCR4
and HIF pathways, in addition to targeting Treg may be
beneficial for this subset of breast cancers that are less
likely to respond to conventional therapies.
Materials and methods
Patient characteristics
The flow of patients through the study as per the
REporting recommendations for tumour MARKer prog-
nostic studies (REMARK) criteria [36] is as follows. Six
hundred and twenty-one invasive breast carcinomas,
characterised in a previous study [32], were retrospec-
tively collected from the John Radcliffe Hospital, Oxford,
UK and from the Garvan Institute of Medical Research,
Sydney, Australia. Of the 621 tumours, 594 tumours
had tissue available for tissue microarray (TMA) con-
struction, of which 491 tumours were available for
FOXP3 staining due to core drop-out. A subset of these
tumours (254 cases) was also stained for CXCL12.
Arrays contained duplicate cores (1 mm cores). FOXP3/
CXCR4 double staining and CA9 staining were per-
formed on whole stained sections of 10 grade 3 basal-
like and 11 grade 3 luminal cancers from the Peter Mac-
Callum Cancer Centre. A waiver for informed consent,
for the use of archival material, has been obtained as
part of Ethics Committee approvals (JR C02.216, HREC
SVH H94/080 and PMCC 09/36). All patients had oper-
able breast carcinomas and were not diagnosed with
metastatic disease at the time of presentation. Median
age of patients included in this study was 55 years
(range 24 to 87 years). Median tumour size was 20 mm
and the median tumour grade was 2. Forty-four percent
of patients had nodal disease. Sixty-eight percent of
tumours were ER positive and 16% were HER2 positive.
A total of 198 patients (31.9%) received adjuvant che-
motherapy (cyclophosphamide, methotrexate and
5-fluorouracil (CMF) or adriamycin and cyclophospha-
mide (AC)). Adjuvant tamoxifen was given to 222
(35.7%) patients. Patients were followed-up for a median
period of 131.9 months. During this time, 137 patients
developed recurrence (30.0%) and 99 deaths (21.7%)
were considered breast-cancer related.
Immunohistochemistry and scoring
Paraffin embedded tissues were dewaxed. For FOXP3
and CA9 staining, antigen retrieval was performed by
microwaving in 50 mmol/L Tris/2 mmol/L EDTA (pH
9.0). Labelling was performed using the mouse monoco-
lonal antibodies 236A/E7 (FOXP3, Abcam, Cambridge,
UK) at 10 μg/mL [11] and M75 (CA9) at 1:100 [32]. For
CXCL12 immunohistochemistry, antigen retrieval was
performed using the DAKO PT Link retrieval system
(Glostrup, Denmark) at high pH for 20 minute at 100°C.
Labeling was performed using mouse CXCL12 antibody
(R&D Systems, Minneapolis, MN, USA, MAB350) [37]
diluted to 8 μg/mL. Labeling was detected using the
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stained with haematoxylin. Positive and negative staining
controls for both antibodies were carried out in parallel
using tonsillar tissue.
Double immunohistochemical staining on whole sec-
tions for FOXP3 and CXCR4 was performed using the
Ventana Benchmark
® ULTRA system (Tucson, Ari-
zona, USA). Antigen retrieval was performed using
Ventana ULTRA Cell Conditioning 1 (95°C for 36 min-
utes). Sections were incubated with FOXP3 antibody
(10 μg/mL) for 20 minutes (room temperature), fol-
lowed by visualization with Ventana Ultraview Univer-
sal DAB. This was followed by incubation with
polyclonal rabbit CXCR4 antibody (Sigma, St Louis,
M O ,U S A ,C 3 1 1 6 )a t4μg/mL [38] for 16 minutes
(room temperature) and visualization with Ventana
Ultraview Alkaline Phosphatase Red Detection Kit.
Centroblasts and centrocytes within lymph node germ-
inal centres were used as positive and negative controls
respectively [39].
Cores were available for 456 tumours to be classified
into four intrinsic subgroups, based on ER, HER2 in situ
hybridization, EGFR and CK5/6 staining, as per Nielson
et al. [16] and Millar et al. [40]: basal-like group (ER
negative, HER2 negative, CK5/6 and/or EGFR positive),
luminal group (ER positive, HER2 negative), HER2
group (HER2 positive) and a negative group (ER, HER2,
CK5/6 and EGFR negative). Absolute numbers of
FOXP3-positive, Treg lymphocytes in assessable 1-mm
diameter invasive tumour cores were counted manually
(Figure 1a). A cut-off of 15 Treg per core was used to
divide the tumours into two groups (as previously
defined by Bates et al. [11]) The level of staining for
CXCL12 was scored with respect to the intensity and
percentage of staining in the cytoplasm. The scoring
system for intensity was: 0 = no staining, 1 = weak
staining, 2 = moderate staining, 3 = strong staining. The
percentage of tumour cells stained in the given core
s c o r e da s :0 %=0 ;1t o1 0 %=1 ;1 1t o5 0 %=2 ;5 1t o
80% = 3; 81 to 100% = 4. The CXCL12 scores for both
staining intensity and the percentage of positive tumour
cells were added together to give a maximum score of 7.
A CXCL12 cut-off score of 7 was used to divide the
tumours into approximately two equal groups (Figures
1b, c). For FOXP3/CXCR4 double staining, the number
of Treg co-expressing FOXP3/CXCR4 was enumerated
from four (x40, 0.55 mm diameter) high power fields of
lymphoid rich infiltrate (approximately equal to 0.95
mm
2) within the tumour (Figures 1d, e). For CA9 stain-
ing, positive expression was defined as the presence of
strong membranous staining in ≥10% of tumour cells
(Figure 1f) [32,41].
Statistical methods
Group comparisons were made for non-thresholded
data using unpaired t test, and for thresholded data
using the chi square test. Kaplan-Meier survival curves
were plotted using breast cancer related death as the
endpoint and compared using a log rank test. Binary
logistic regression was used for multivariate analyses
and the Cox proportional hazard regression model was
used to identify independent prognostic factors for over-
all survival. Analyses were performed with SPSS 16.0
(SPSS Inc., 233 South Wacker Drive, Chicago, IL, 60606,
USA). A two-tailed P-value test was used in all analyses
and a P-value of less than 0.05 was considered statisti-
cally significant.
Results
Tumour infiltration by Treg correlates with tumour
CXCL12 expression and basal phenotype
The number of Treg was correlated with clinicopatholo-
gical parameters (Table 1). In a univariate analysis,
tumours with high Treg (defined as ≥15 Treg per core)
were significantly more frequently grade 3 tumours
(115/224, 51%), compared with tumours with low Treg
(80/259, 31%) (P < 0.001). Compared to low Treg
tumours, high Treg tumours also significantly correlated
with negative ER status (73/262 (28%) and 81/216 (38%)
ER negative respectively, P = 0.025), positive HER2 sta-
tus (7/245 (3%) and 20/206 (10%) HER2 positive respec-
tively, P = 0.002) and positive CXCL12 expression (74/
125 (59%) and 83/110 (75%), P = 0.008). No correlation
was observed between Treg and nodal status, (P =
0.062), endocrine therapy (P = 0.255) and chemotherapy
(P = 0.148). Basal-like cancers were more likely to have
high Treg (36/55, 75%, median 25.46) compared with
luminal cancers (99/258, 38%, median 7.64) (P <0 . 0 0 1 ,
Table 2).
I nam u l t i v a r i a t ea n a l y s i su s i n gt h eb i n a r yl o g i s t i c
regression model, high Treg significantly correlated with
basal-like phenotype (OR 3.14, 95% CI 1.08 to 9.17, P =
0.004) and CXCL12 expression (OR 1.89, 95% CI 1.22
to 2.94, P = 0.004), but not tumour grade (OR 1.43, 95%
CI 0.88 to 2.32, P = 0.151, Table 3).
High Treg infiltration is associated with reduced breast
cancer-specific survival in luminal and basal-like cancers
High tumour infiltration by Treg (≥15) was significantly
associated with reduced breast cancer specific survival
(P = 0.001), with divergence of the survival curves occur-
ring two years after initial surgical treatment (Figure 2a).
The association of high Treg infiltration with poorer sur-
vival in all tumours was confirmed in a multivariate ana-
lysis including age, lymph node status, grade, size, ER,
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1.62, 95% CI 1.02 to 2.55, P = 0.040) (Supplementary
Table S1a in Additional file 1).
Breast cancer-specific survival based on Treg infiltra-
tion was analysed for each intrinsic subtype. High Treg
infiltration correlated with poorer survival in luminal (P
< 0.001) (Figure 2b) and basal-like cancers (P = 0.040)
(Figure 2c), but not in HER2 (P = 0.255) or null type
cancers (P = 0.128).
Treg infiltration was associated with reduced breast can-
cer-specific survival in patients treated with hormone ther-
apy (P = 0.001) (Figure 2d). This was confirmed in a
multivariate analysis where high Treg were an indepen-
dent predictor of a poor response to hormone therapy
(OR 1.78, 95% CI 1.01 to 3.15, P = 0.040) (Supplementary
Table S1b in Additional file 1). No differences in survival
were observed for patients treated with chemotherapy
when stratified by Treg infiltration (P = 0.565)
CXCL12 expression does not differ between the different
intrinsic subtypes, and is associated with longer survival
Although a smaller proportion of basal-like (16/27, 59%)
and HER2 tumours (25/47, 53%) was positive for
CXCL12 expression compared with luminal tumours
(102/138, 74%), this did not reach statistical significance
(P = 0.050) (Table 2). There was no correlation between
CXCL12 expression and tumour size, grade, lymph node
status, ER, endocrine treatment and chemotherapy (all
P > 0.05) (Supplementary Table S2 in Additional file 1).
On a log rank test, positive CXCL12 expression corre-
lated with longer breast cancer-specific survival (P =
0.024) (Figure 2e).
Figure 1 Immunohistochemistry for FOXP3, CXCL12, CXCR4 and CA9. Immunohistochemical staining for (A) FOXP3 positive tumour
infiltrating Treg (x20), (B) Tumour cells negative for CXCL12 (x10), (C) Tumour cells showing strong positivity for CXCL12 (x10). (D, E) Double
immunohistochemical staining for FOXP3 (brown, nuclear) and CXCR4 (red, cytoplasmic). (D) CXCR4 negative Treg (x40), (E) CXCR4 positive Treg
(arrows) (x40), Inset (x100 oil immersion), (F) Tumour cells with positive CA9 staining.
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Carbonic anhydrase IX (CA9) is a transmembrane pro-
tein involved in maintaining a low pericellular pH
through the conversion of carbon dioxide to carbonic
acid [42]. Its expression has been shown to correlate
with hypoxia as measured by Eppendorf microelectrode
[43] and the distribution of pimonidazole (a chemical
marker of hypoxia) [42,44].
CA9 expression was correlated with Treg numbers in
448 breast cancers: increased numbers of Treg were
observed in CA9 positive tumours (median Treg = 32, n
= 66) compared to CA9 negative tumours (median Treg
= 10, n = 382) (Mann-Whitney U P < 0.001). In order
to further explore whether Treg recruitment was asso-
ciated with hypoxia or other factors expressed by the
basal subtype, we correlated Treg numbers with CA9
expression in a subset of 327 non-basal breast cancers.
Table 1 Correlation of FOXP3 Treg with
clinicopathological parameters and CXCL12 expression
Treg < 15 Treg ≥15 P-value
Tumour size (mm)
Median 21.2 23.8 0.571
Tumour grade < 0.001
1 56 (22%) 25 (11%)
2 123 (47%) 84 (38%)
3 80 (31%) 115 (51%)
Nodal status 0.062
Negative 154 (59%) 109 (51%)
Positive 107 (41%) 107 (49%)
ER 0.025
Negative 73 (28%) 81 (38%)
Positive 189 (72%) 135 (62%)
HER2 0.002
Negative 238 (97%) 186 (90%)
Positive 7 (3%) 20 (10%)
CXCL12 0.008
Negative 51 (41%) 27 (25%)
Positive 74 (59%) 83 (75%)
Endocrine Rx 0.255
Negative 99 (37%) 72 (32%)
Positive 167 (63%) 151 (68%)
Chemotherapy 0.148
Negative 168 (64%) 127 (57%)
Positive 96 (35%) 95 (43%)
ER, estrogen receptor; Rx, therapy.
Table 2 Correlation analysis of intrinsic subtypes with clinicopathological parameters, Treg and CXCL12 expression (n
= 456)
Luminal (n = 289) HER2 (n = 75) Basal-like (n = 62) Negative (n = 30) P-value
Patient age
Median (years) 56.0 55.2 54.0 52.7 0.64
Tumour size
Median 18.0 22.0 22.5 20.5 0.40
Tumour grade < 0.001
1 71 (25%) 4 (5%) 2 (3%) 4 (13%)
2 156 (55%) 16 (22%) 12 (20%) 12 (40%)
3 58 (20%) 54 (73%) 47 (77%) 14 (47%)
Nodal status 0.75
Negative 162 (56%) 40 (54%) 34 (55%) 17 (57%)
Positive 125 (44%) 34 (46%) 28 (45%) 13 (43%)
Treg < 0.001
< 15 159 (62%) 28 (39%) 19 (25%) 23 (92%)
≥15 99 (38%) 43 (61%) 36 (75%) 2 (8%)
median 7.64 33.54 25.46 0.83
CXCL12 0.050
Negative 36 (26%) 22 (47%) 11 (41%) 6 (35%)
Positive 102 (74%) 25 (53%) 16 (59%) 11 (65%)
Treg, regulatory T cells.
Table 3 Multivariate analysis, correlation of high Treg
(≥15) with tumour size, grade, CXCL12 and tumour type
Odds ratio 95% CI P-value
Tumour size 0.56 0.27 to 1.14 0.560
Grade 1.43 0.88 to 2.32 0.151
CXCL12 1.89 1.22 to 2.94 0.004
Tumour type
Luminal (baseline) 1.00 - -
Basal-like 3.14 1.08 to 9.17 0.004
n = 165
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Treg (median Treg = 21 per 1 mm core, n = 32) com-
pared to CA9 negative non-basal cancers (median Treg
=8p e r1m mc o r e ,n=2 1 )( M a n n - W h i t n e yUP =
0.044). These results suggest hypoxia promotes Treg
recruitment independent of basal subtype.
Infiltration by CXCR4 positive Treg correlates with basal
phenotype and tumour hypoxia
Double CXCR4/FOXP3 immunoperoxidase staining was
performed to evaluate CXCR4 positive Treg infiltration
in whole stained sections from 10 grade 3 basal-like and
11 grade 3 luminal cancers. A higher proportion of Treg
Figure 2 Kaplan Meier curves, breast cancer specific survival. Kaplan Meier curves, breast cancer specific survival, (A) all cancers stratified by
Treg infiltration (n = 479, P = 0.001), (B) luminal cancers stratified by Treg infiltration (n = 258, P < 0.001), (C) basal-like cancers stratified by Treg
infiltration (n = 54, P = 0.040), (D) patients treated with hormone therapy (n = 309, P = 0.001), (E) all cancers stratified by CXCL12 expression (n
= 236, P = 0.005),
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interquartile range = 4.9% to 38.1%), when compared to
luminal cancers (median = 3.2%, interquartile range =
2.1% to 19.9%) (P = 0.029) (Figure 3a). No difference in
CXCR4 positive Treg was observed between the peritu-
moural stroma and the tumour bed (P = 0.337).
Using CA9 as a surrogate marker of hypoxia, in keep-
ing with our previous studies [32], grade 3 basal-like
tumours were more likely to be hypoxic (8/10 positive
for CA9), compared to grade 3 luminal cancers (0/11
positive for CA9) (P < 0.001). Furthermore, in hypoxic
tumours with positive CA9 expression, a higher propor-
tion of Treg was positive for CXCR4 (median = 18.1%,
interquartile range = 9.7% to 40.3%) compared to CA9
negative tumours (median = 4.3%, interquartile range =
2.1% to 19.9%) (P = 0.049) (Figure 3b).
Discussion
In view of the association among basal-like breast can-
cer, its dense lymphoid infiltrate and aggressive beha-
viour, we hypothesized that basal-like tumours evade
the anti-tumour immune response via the recruitment
of Treg. In our study, basal-like tumours were associated
with high Treg and a four-fold increase in the median
number of Treg compared with luminal tumours.
Furthermore, this association was independent of
tumour size and grade and conferred a poor survival in
this subtype. These results are in keeping with our pre-
vious study in an independent cohort where Treg infil-
tration correlated with high tumour grade, HER2
positivity, ER negativity and poor survival [11]. and with
Bohling et al. [45] in their comparison of 26 grade 3 tri-
ple negative cancers with 71 non-grade 3 non-triple
negative cancers.
Although high Treg were also associated with an
adverse outcome in luminal cancers in our cohort of
HER positive patients, who were not treated with trastu-
zumab, accumulation of Treg did not correlate with sur-
vival. Although the reason for the latter result is
unclear, one potential explanation is Treg immune sup-
pression may have no effect on an immune response
which is ineffective in the first instance. This is sup-
ported by studies where the anti-tumour immune
response against HER2 cancers could be boosted by an
infusion of HER2 specific T cells [46].
A number of chemokines have been implicated in the
recruitment of Treg in non-neoplastic tissues [18].
Recent studies on breast cancers have shown that two
of these chemokines, CCL20 [13] and CCL22 [12], may
recruit Treg that express the corresponding chemokine
receptors CCR6 and CCR4. Our results demonstrate
CXCL12 derived from tumour cells may also be
involved in Treg recruitment. While tumour CXCL12
expression correlated with tumour Treg recruitment,
this did not appear to account for the increased number
of Treg observed in basal-like cancers. Indeed, a lower
proportion of basal-like cancers expressed CXCL12
(59%) compared with luminal cancers (74%). Our find-
ings suggest preferential Treg recruitment in basal-like
cancers may be in part explained by CXCR4 up-regula-
tion in Treg. This is supported by in vitro cell migration
assays where induction of CXCR4 expression in Treg
resulted in their migration towards a CXCL12 gradient
[19,20], and could be terminated by incubation with an
anti-CXCR4 antibody [19]. Preferential accumulation of
CXCR4 positive Treg, and its correlation with tumour
CXCL12 expression, has also been previously demon-
strated in adenocarcinomas of the lung [20] and malig-
nant mesothelioma [21].
Figure 3 CXCR4 expression in Treg. (A) Proportion of Treg
expressing CXCR4 in basal (median = 18.1%, interquartile range =
4.9% to 38.1%) vs. luminal cancers (median = 3.2%, interquartile
range = 2.1% to 19.9%) (P = 0.029). (B) Proportion of Treg
expressing CXCR4 in CA9 positive (median = 18.1%, interquartile
range = 9.7% to 40.3%) vs. CA9 negative cancers (median = 4.3%,
interquartile range = 2.1% to 19.9%) (P = 0.049).
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the CXCR4 receptor. It is also the only ligand for the
CXCR4 receptor [47]. CXCR4 expression is induced by
hypoxia [24,48]. Using CA9 as a surrogate marker of
hypoxia [42-44], we demonstr a t e dt h a th y p o x i ai sa s s o -
ciated with the accumulation of Treg and also the sub-
set of CXCR4 positive Treg in breast cancer. This,
together with our previous finding that hypoxia is a fea-
ture of basal-like breast cancers, suggests increased Treg
infiltration in basal-like cancers may be in part due to
hypoxia-induced up-regulation of CXCR4 in Treg. The
correlations identified in our study are mechanistically
supported by in vitro studies, where T cells incubated
under hypoxic conditions show a time-dependent
increase in HIF-1a [29-31]. Furthermore, the link
between HIF-1a and CXCR4 expression is supported by
a number of findings [24] including: a) reduction of
CXCR4 in VHL mutated cell lines [24], b) increased IL-
2 receptor (also implicated in CXCR4 up-regulation),
and reduced CCR6 (another receptor implicated in Treg
recruitment) expression in T cells stimulated by hypoxia
[31], c) HIF-1a recruitment to the CXCR4 promoter in
the hypoxic state [24] and d) hypoxia-induced expres-
sion of CXCR4, but not CCR6, CCR7, CXCR3 or
CXCR5 [23]. HIF-1a m a ya l s oi n d u c eC X C R 4e x p r e s -
sion indirectly by up-regulating the expression of
FOXP3, which binds regulatory sequences upstream of
the transcriptional start site of CXCR4 resulting in
CXCR4 over-expression [49]. Furthermore, hypoxia
increases the potency of Treg in suppressing the prolif-
eration of effector CD4+ T cells [29,50]. There are likely
also to be other cytokines regulating T cell recruitment
and a comprehensive analysis of hypoxia-induced cyto-
kines and their cognate receptors would be valuable, but
need to be directed by detailed analysis of pathways
regulated in these cells in vitro. The effect of hypoxia on
Treg appears to be independent of other factors
expressed by the basal subtype as the correlation
between hypoxia and Treg was re-duplicated in non-
basal tumours.
Loss of CXCL12 expression, in this study and in pre-
vious studies [51], is associated with a poor prognosis.
Tumour cells with reduced CXCL12 in their immediate
microenvironment may be at an advantage to receive
endocrine CXCL12 signals, promoting their migration
towards ectopic sources of the CXCR4 ligand. This is
supported by mouse models where metastasis of tumour
xenografts to the lung may be inhibited by endogenous
CXCL12 expression in the xenografted tumour [52].
While CXCL12 expression is associated with a favour-
able prognosis in an analysis of all breast cancers, there
may be significant heterogeneity in the impact of
CXCL12 on tumour behaviour between subtypes. For
example, while CXCL12 is associated with a good
prognosis in non-basal breast cancers (log rank test P =
0.002), but no such correlation is seen for basal cancers
(P = 0.688). In the setting of profound hypoxia and
CXCR4 up-regulation in Treg, as occurs in basal-like
breast cancer, CXCL12 may have a negative conse-
quence of enhancing Treg recruitment and suppressing
the anti-tumour immune response. Although CXCL12
may also recruit other T cell subsets, it appears to pre-
ferentially recruit Treg, rather than CD8 cytotoxic or
CD4 helper T cells [20,53].
Conclusions
These findings have important implications, as they sug-
gest basal-like cancers, which are traditionally resistant to
targeted therapies and may potentially respond to immu-
notherapy targeting Treg. Furthermore, Treg recruitment
by CXCL12/CXCR4 in these cancers may potentially be
modulated by treatment directed against the HIF-1a
pathway. Thus there is an opportunity for clinical trials
based on robust reagents directed against Treg, or antibo-
dies blocking CXCR4, to stratify patients for anti-HIF
therapies. Indeed, many potent HIF-1 inhibitors are
FDA-approved cancer treatment agents including anthra-
cyclines and topotecan enabling clinical trials to test their
effectiveness [54,55]. Side effects should be minimal since
these agents are chronically administered at low dose to
derive their anti-HIF activity. There are some data to sug-
gest that the anthracycline analogue, mitoxanthrone, low-
ers the number of Treg in tumours [56] and such agents
may be combined with multiple immunotherapy strate-
gies that also reduce Treg numbers, enabling an
improved effector cell response to a vaccine.
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